Givlaari
Payments companies reported to CMS as associated with Givlaari. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Givlaari, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Givlaari
These are the largest totals companies reported as associated with Givlaari. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Robert Schwartz | New York, NY | Internal Medicine | $59,009.03 |
| Elizabeth Bowhay-Carnes | San Antonio, TX | Hematology & Oncology | $37,464.15 |
| Angelika Erwin | Cleveland, OH | Clinical Genetics (M.D.) | $32,036.46 |
| Brooks Cash | Houston, TX | Gastroenterology (Internal Medicine) | $31,335.69 |
| Bruce Wang | San Francisco, CA | Gastroenterology (Internal Medicine) | $23,704.15 |
| Simon Beaven | Los Angeles, CA | Internal Medicine | $20,858.50 |
| Ilene Weitz | Los Angeles, CA | Hematology (Internal Medicine) | $11,390.20 |
| Manish Thapar | Philadelphia, PA | Transplant Hepatology | $10,523.26 |
| Sanjaykumar Hapani | Edmond, OK | Hematology & Oncology | $6,827.34 |
| Sean Rudnick | Charlotte, NC | Gastroenterology (Internal Medicine) | $6,323.12 |
Prescribed Givlaari?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.